Propanc Biopharma, Inc. (PPCB)
NASDAQ: PPCB · Real-Time Price · USD
0.9210
-0.0218 (-2.31%)
At close: Sep 11, 2026, 4:00 PM EDT
0.9010
-0.0200 (-2.17%)
After-hours: Sep 11, 2026, 7:38 PM EDT
Propanc Biopharma Employees
As of June 30, 2025, Propanc Biopharma had 2 total employees, including 1 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
2
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$9,646,588
Market Cap
2.10M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2025 | 2 | 0 | - | 1 | 1 |
| Jun 30, 2024 | 2 | 0 | - | 1 | 1 |
| Jun 30, 2023 | 2 | -1 | -33.33% | 1 | 1 |
| Jun 30, 2022 | 3 | 1 | 50.00% | 1 | 2 |
| Jun 30, 2021 | 2 | -1 | -33.33% | 1 | 1 |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Valion Bio | 52 |
| Virax Biolabs Group | 26 |
| Curis | 24 |
| Silexion Therapeutics | 14 |
| Genprex | 13 |
| Decoy Therapeutics | 11 |
| Artelo Biosciences | 7 |
| Jupiter Neurosciences | 5 |
PPCB News
- 3 days ago - Propanc Biopharma to commence first-in-human study of PRP in February - TheFly
- 3 days ago - Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027 - GlobeNewsWire
- 16 days ago - Why Is Penny Stock Propanc Biopharma (PPCB) Up 245% Today? - TipRanks
- 16 days ago - Propanc Biopharma announces new preclinical data for PRP in PDAC - TheFly
- 16 days ago - Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit - GlobeNewsWire
- 25 days ago - Propanc Biopharma starts finalization of clinical trial protocol for PRP study - TheFly
- 25 days ago - Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP - GlobeNewsWire
- 26 days ago - Propanc highlights PRP as potential therapy against RAS-driven cancers - TheFly